Sarepta Therapeutics
SRPT
134 hedge funds and large institutions have $1.29B invested in Sarepta Therapeutics in 2013 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 40 reducing their positions, and 19 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
48% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 40
42% more capital invested
Capital invested by funds: $904M → $1.29B (+$381M)
37% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 19
5% more funds holding
Funds holding: 128 → 134 (+6)
30% less call options, than puts
Call options by funds: $175M | Put options by funds: $250M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$35.1M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$21.3M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$20.9M |
| 4 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$19.3M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$33M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$25.4M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21.5M |
| 4 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$13.7M |
| 5 |
Barclays
London,
United Kingdom
|
-$9.5M |
SRPT Hedge Fund Activity: Q3 2013 in Review
134 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2013, worth a combined $1.29B — up 42% from $904M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SRPT positions and 19 closed out — a net gain of 7 holders — while 59 added to existing stakes and 40 trimmed.
The largest buyer was SAC Capital Advisors, adding an estimated $35.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $33M.
- 134 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2013, up from 128 in Q2 2013.
- Funds reported $1.29B of Sarepta Therapeutics stock for Q3 2013, up 42% quarter-over-quarter.
- 26 funds opened new Sarepta Therapeutics positions in Q3 2013 and 19 closed out, a net change of +7 holders.
- The largest Sarepta Therapeutics buyer in Q3 2013 was SAC Capital Advisors, an estimated $35.1M added.
- The largest Sarepta Therapeutics seller in Q3 2013 was T. Rowe Price Associates, an estimated $33M sold.
Based on aggregated 13F filings for Q3 2013.